



HPV DNA Positive Control





MEDIMARK® Europe 11, rue Émile Zola BP 2332 38033 Grenoble Cedex 2 - France + 33 (0) 4 76 86 43 22 info@medimark-europe.com

About this package insert

Thank you for your interest in this ACCURUN product.

This package insert consists of two pages.

The first page contains the product name and an explanation of the symbols used on the labeling.

The second page contains the complete package insert text.

If the package insert you view or print does not contain two pages, or if you experience any problems, please email us at info@seracare.com. By phone: US customers call 800.676.1881; International customers call collect 508.634.3359.

A printed package insert will be sent to you upon request.



25 Birch Street, Milford, MA 01757 USA SeraCare Life Sciences, Inc.

Phone: 001.508.244.6400 info@seracare.com

July 2011 12335GB-01

Explanation of symbols used in SeraCare product labeling



Upper limit of temperature







CONTROL +

Positive control



Temperature limitation



Use By



Catalogue number





Highly flammable



"Caution, consult accompanying documents"



Authorized Representative in the European Community



In Vitro Diagnostic Medical Device



Toxic by inhalation, in contact with skin and if swallowed





HPV DNA Positive Control

THESE REAGENTS MUST NOT BE SUBSTITUTED FOR THE MANDATORY POSITIVE AND NEGATIVE CONTROL REAGENTS PROVIDED WITH MANUFACTURED TEST KITS.

NAME AND INTENDED USE

ACCURUN whole cell controls are designed to evaluate laboratory testing precision and can be used to detect errors in laboratory testing procedures. ACCURUN 372® HPV DNA Positive Control Series 400 is formulated for use with laboratory tests that detect Human Papillomavirus (HPV) DNA in human cervical samples collected in SurePath™ transport medium. For In Vitro Diagnostic Use.

Frequent testing of independent quality control samples provides the analyst with a means of monitoring the performance of laboratory assays. Routine use of controls that closely mimic patient samples allows laboratories to detect immediate analytical errors and monitor long term performance and can assist in identifying increases in random or systematic errors. A well designed quality control program can provide added confidence in the reliability of results obtained for unknown specimens. The use of independent whole cell controls may provide valuable information concerning laboratory proficiency and kit lot variation that may affect assay sensitivity

PRINCIPLES OF THE PROCEDURE

ACCURUN 372 HPV DNA Positive Control Series 400 is designed for use with laboratory testing for HPV DNA, to monitor test performance. ACCURUN 372 HPV DNA Positive Control Series 400 is manufactured from cultured human epithelial cells (SiHa) that contain an integrated genome of HPV type 16². SiHa cells are mixed with noninfected cultured human cells and suspended in a buffered solution. A separate diluent vial containing SurePath transport medium (BD, Franklin Lakes, NJ) is supplied with each cell suspension vial. The diluent is added to the cell suspension vial, the resulting solution is mixed, and the sample is processed according to the procedure for testing unknown samples.

REAGENTS

10 vials, 0.8 ml cell suspension per vial Cat. No. A372-4034-E

10 vials, 2.0 ml diluent per vial

WARNINGS AND PRECAUTIONS

For In Vitro Diagnostic Use.

CAUTION: Handle ACCURUN controls and all human blood products as though capable of transmitting infectious agents. ACCURUN 372 HPV DNA Positive Control Series 400 is manufactured from HPV infected human epithelial cells and other non-infected cells that are grown in tissue culture and preserved in a buffered solution.

Safety Precautions

Use Centers for Disease Control (CDC) recommended universal precautions for handling ACCURUN and human specimens³. Do not pipette by mouth; do not smoke, eat or drink in areas where specimens are being handled. Clean any spillage by immediately wiping up with 0.5% sodium hypochlorite solution. Dispose of all specimens, controls and materials used in testing as though they contain infectious agents

ACCURUN 372 HPV DNA Positive Control Series 400 must be disposed of by following RCRA ID#D001 guidelines for ignitable waste⁴. Keep ACCURUN 372 HPV DNA Positive Control Series 400 closed when not in use; avoid direct inhalation of the solution and use with ventilation.

Handling Precautions

Do not use ACCURUN controls beyond the expiration date. Avoid contamination of controls when opening and closing the vials. ACCURUN 372 diluent contains a FLAMMABLE liquid; keep away from all sources of ignition.

STORAGE INSTRUCTIONS

Store ACCURUN 372 HPV DNA Positive Control Series 400 at 2-8°C until use. Once opened. ACCURUN 372 should not be reused. Store vials upright to prevent leakage

INDICATIONS OF REAGENT INSTABILITY OR DETERIORATION

ACCURUN 372 HPV DNA Positive Control Series 400 contains a suspension of fixed cells in buffered solution and may therefore exhibit slight cloudiness. Excessive turbidity may indicate instability or deterioration of ACCURUN 372 and such solutions should be discarded.

PROCEDURE

Materials Provided

ACCURUN 372 HPV DNA Positive Control Series 400 is manufactured from HPV infected human epithelial cells and other non-infected cells that are grown in tissue culture and suspended in buffered solution. The ACCURUN 372 diluent is SurePath® transport medium

Materials Required but not Provided

Refer to instructions supplied by manufacturer of the test kit to be used.

Instructions for Use

- Remove one vial labeled "Positive Control" (in conical centrifuge tube) and one vial labeled "Diluent" (in flat bottomed tube) from refrigerator storage and allow to equilibrate to room temperature
- · Add the contents of the Diluent vial to the Positive Control vial. Make sure the Diluent is added to the Positive Control: do not attempt to reverse the procedure.
- Mix by vortexing for 15 seconds to assure a homogeneous cell suspension.
- The cell suspension should be used immediately.
- ACCURUN 372 HPV DNA Positive Control Series 400 should be included in a test run using exactly the same procedure that is used to run the unknown specimens collected in SurePath

ACCURUN controls must NOT be substituted for the positive and negative control reagents provided with the manufactured test kit.

Quality Control

ACCURUN 372 HPV DNA Positive Control Series 400 does not have an assigned value. It is recommended that each laboratory establish an acceptance range for each lot of ACCURUN 372 with each assay procedure prior to its routine use in the laboratory.

INTERPRETATION OF RESULTS

Levels of reactivity of ACCURUN 372 HPV DNA Positive Control Series 400 may vary with different manufacturer's tests and different test kit lots. Since the control does not have an assigned value, the laboratory must establish an acceptance range for each lot of ACCURUN 372 HPV DNA Positive Control Series 400. When results for ACCURUN 372 are outside of the established acceptance range, it may be an indication of unsatisfactory test performance. Possible sources of error include: deterioration of test kit reagents, operator error, faulty performance of equipment, or contamination of reagents

LIMITATIONS OF THE PROCEDURE

ACCURUN CONTROLS MUST NOT BE SUBSTITUTED FOR THE POSITIVE AND NEGATIVE CONTROL REAGENTS PROVIDED WITH MANUFACTURED TEST KITS.

TEST PROCEDURES and INTERPRETATION OF RESULTS provided by manufacturers of test kits must be followed closely. Deviations from procedures recommended by test kit manufacturers may produce unreliable results. ACCURUN controls are not calibrators and should not be used for assay calibration. Performance characteristics for ACCURUN 372 HPV DNA Positive Control Series 400 have been established only for HPV DNA. Adverse shipping and storage conditions or use of outdated controls may produce erroneous results.

EXPECTED RESULTS

ACCURUN 372 HPV DNA Positive Control Series 400 DOES NOT HAVE AN ASSIGNED

VALUE. Specific levels of reactivity will vary among difference manufacturers' assays, different procedures, different lot numbers, and different laboratories. Procedures for implementing a quality assurance program and monitoring test performance on a routine basis must be established by each individual laboratory. Each laboratory should establish its own range of acceptable values. For example, the acceptable range might include all values within 2 standard deviations of the mean of 20 data points obtained in 20 runs over a period of 30 days6.

Table 1 describes the expected result for ACCURUN 372 HPV DNA Positive Control Series 400 in units as specified by the assay manufacturer

SPECIFIC PERFORMANCE CHARACTERISTICS

ACCURUN Controls are designed for use with laboratory testing for the purposes of monitoring assay performance. ACCURUN 372 HPV DNA Positive Control Series 400 is manufactured from human epithelial cells obtained from tissue culture, mixed with non-infected cells suspended in buffered solution, and is supplied with a separate vial of SurePath diluent. ACCURUN controls do not have assigned values. Specific levels of reactivity will vary among different manufacturers' assays, different procedures, different lot numbers, and different laboratories. Procedures for implementing a quality assurance program and monitoring test performance on a routine basis must be established by each individual laboratory.

ACKNOWLEDGEMENT

The SiHa cells used in this product were developed by Dr. Yohei Ito² and were provided in accordance with a Biological Agreement with the U.S. Public Health Services.

- Green IV GA, Carey RN, Westgard JO, Carten T, Shablesky LA, Achord D, Page E, and Le AV. Quality control for qualitative assays: quantitative QC procedure designed to assure analytical quality required for an ELISA for hepatitis B surface antigen. Clin. Chem. 43(9): 1618-1621, 1997.
- Ito Y. Studies on a human cell line (SiHa) derived from carcinoma in uterus. I. Its establishment and morphology. Proc. Soc. Exp. Biol. Med. 135:2 543-545, 1970.
- CDC Recommendations for prevention of HIV transmission in health care settings. MMWR 36 (suppl. 2), 1987.
- Treatment standards for hazardous waste; 40 CFR 268.40 Subpart D. D001: Ignitable characteristics of waste
- Davis K. Pavne E. Jafri S. Cullen A. Avissar P and Malinowski D. An evaluation of the rapid capture systems for High-Risk HPV Hybrid Capture II testing of cervical specimens collected in TriPath ŚurePath medium. In 21st Annual Clin. Virol. Symp. & Annual Meeting Pan Amer. Soc. Clin. Virol., May 8 2005, page #TA3S (Abstract).
- Statistical Quality Control for Quantitative Measurements: Principles and Definitions; Approved Guideline—Second Edition. NCCLS document C24-A2, 1999.

Table 1. Typical Data for ACCURUN 372 HPV DNA Positive Control Series 400.

Manufacturer	Assay	Typical Data
Qiagen:	digene HC2 Hybrid Capture DNA Test,	High-Risk Probe:
Valencia, CA	Product Code 5101-1096	Positive

For assistance, contact SeraCare Technical Support at 001.508.244.6400.



July 2011 12335GB-01

PHONE: 001.508.244.6400 FAX: 001.508.634.3394 Toll Free (US only): 800.676.1881 www.seracare.com